Introduction to Symposium

Singh, Bramah N.
December 1986
Angiology;Dec1986 Part 2, Vol. 37 Issue 12, p929
Academic Journal
The article presents an introduction to a symposium, which was held on November 14, 1985 at Hilton Head Island in South Carolina. Furthermore, it states that in the last decade or so numerous metabolites of antiarrhythmic agents, new and old, have been shown to exhibit properties independently of the parent compound. Such metabolites have included the results of biotransformation of procainamide, encainide, lorcainide, and amiodarone among others. The papers presented at the symposium provide the background to the evolving role of the drug in the control of cardiac arrhythmias.


Related Articles

  • Amiodarone-associated Proarrhythmic Effects. Hohnloser, Stefan H.; Klingenhehen, Thomas; Singh, Bramah N. // Annals of Internal Medicine;10/1/94, Vol. 121 Issue 7, p529 

    Assesses the incidence of amiodarone-mediated aggravation of ventricular tachyarrhythmias or the development of arrhythmias in patients with cardiac disease. Therapeutic function of amiodarone; Use of amiodarone in patients with previous drug-induced torsade de pointes; Overview of...

  • Advances in arrhythmia management. Postigo, Angel Iglesias; Hall, Angela // British Journal of Cardiac Nursing;Dec2009, Vol. 4 Issue 12, p596 

    Information about the activities and topics discussed at the Heart Rhythm Congress 2009 held in Birmingham on October 18-21, 2009 is presented. It notes that the 4-day event has been attended by more than 3000 delegates and 200 patients and featured various overseas speakers such as doctor...

  • Arrhythmia Control by Selective Lengthening of Cardiac Repolarization: Role of N--Acetylprocainamide, Active Metabolite of Procainamide. Singh, Bramah N.; Feld, Gregory; Nademanee, Koonlawee // Angiology;Dec1986 Part 2, Vol. 37 Issue 12, p930 

    In recent years, data has become available to support the concept that a selective lengthening of the cardiac action potential (a Class III antiarrhythmic action) by whatever mechanism with an attendant increase in the effective refractory period constitutes a distinct antiarrhythmic mechanism....

  • The Role of Newer Antiarrhythmic Drugs in the Management of Patients with Ventricular Arrhythmias. Cain, Michael E. // Angiology;Jul1988 Part 2, Vol. 39 Issue 7, p668 

    The purpose of this review is to discuss the role of mexiletine, to-cainide, flecainide, and amiodarone in the treatment of patients with symptomatic ventricular ectopy or sustained ventricular tachycardia (VT) and fibrillation (VF). The pharmacologic properties, electrophysio-logic effects,...

  • Dual chamber pacing in patients with severe heart failure on β blocker and amiodarone treatment: preliminary results of a randomised study. Nägele, H.; Schomburg, R.; Petersen, B.; Rödiger, W. // Heart;Jun2002, Vol. 87 Issue 6, p566 

    This article presents a study on the dual chamber pacing in patients with severe heart failure on &b.beta; blocker and amiodarone treatment. A randomised study to test whether DDDR pacing with optimised atrioventricular delay and reversal of drug induced bradycardia by rate responsive pacing was...

  • Amiodarone-induced pulmonary toxicity. Predisposing factors, clinical symptoms and treatment. Jessurun, G.A.J.; Boersma, W.G.; Crijns, H.J.G.M.; Jessurun, G A; Crijns, H J // Drug Safety;May1998, Vol. 18 Issue 5, p339 

    Amiodarone is frequently used for the treatment of cardiac arrhythmias. Although the therapeutic efficacy of amiodarone has been established, its use is limited by its safety profile. Amiodarone-induced pulmonary toxicity is one of the most life-threatening complications of this therapy. It is a...

  • Sarcoid heart disease. Fleming, Hugh A. // British Medical Journal (Clinical Research Edition);4/26/1986, Vol. 292 Issue 6528, p1095 

    Examines the effects of sarcoidosis on the heart in Great Britain. Prevalence of cardiac lesions in patients with sarcoidosis; Use of endomyocardial biopsy in sarcoidosis analysis; Effectiveness of amiodarone in treating resistant arrhythmia.

  • Bilateral thoracoscopic cervical sympathectomy for the treatment of recurrent polymorphic ventricular tachycardia. Turley, A. J.; Thambyrajah, J.; Harcombe, A. A. // Heart;Jan2005, Vol. 91 Issue 1, p15 

    Congenital long QT syndrome (LOTS) is a disorder of prolonged cardiac repolarisation, manifest by a prolonged QT interval and characterised by recurrent presyncope/ syncope, polymorphic ventricular tachycardia (PMVT), or sudden cardiac death. A 46 year old woman with no family history of sudden...

  • Medications Used to Manage Supraventricular Tachycardia in the Infant A North American Survey. K. K. Wong; Potts, J. E.; Etheridge, S. P.; Sanatani, S. // Pediatric Cardiology;Mar/Apr2006, Vol. 27 Issue 2, p199 

    Supraventricular tachycardia is the most common pediatric arrhythmia, but there is no consensus and little evidence to guide its treatment. We sent a questionnaire to pediatric cardiologists in North America to assess the current practice pattern. Of 1534 surveys mailed, 352 (23%) were returned...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics